Elacestrant Improves PFS in ESR1 mutated, ER+/HER2– Breast Cancer
Assessing for ESR1 Expression During Elacestrant for ER+ HER2– Breast Cancer
Future Uses of Elacestrant in Metastatic/Early-Stage Breast Cancer